SPORE in Prostate Cancer

Publications

Found 55 results

Filters: First Letter Of Last Name is P [Clear All Filters]

2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

2018

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al.. 2018. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al.. 2018. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H. 2018. BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.. JCO Precis Oncol. 2

Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J, Palomero L, Farran-Matas S, Rubin MA, Shen MM et al.. 2018. NSD2 is a conserved driver of metastatic prostate cancer progression.. Nat Commun. 9(1):5201.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JMiguel, Chen Y, Rubin MA et al.. 2018. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.. J Clin Invest. 128(1):381-386.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LLazo, Susani M et al.. 2018. Transcriptomic heterogeneity in multifocal prostate cancer.. JCI Insight. 3(21)

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LLazo, Susani M et al.. 2018. Transcriptomic heterogeneity in multifocal prostate cancer.. JCI Insight. 3(21)

2019

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al.. 2019. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al.. 2019. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al.. 2019. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al.. 2019. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al.. 2019. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al.. 2019. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al.. 2019. Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3